Ketorolac for sickle cell vaso-occlusive crisis pain in the emergency department: lack of a narcotic-sparing effect
✍ Scribed by Seth W Wright; Robert L Norris; Thomas R Mitchell
- Publisher
- Elsevier Science
- Year
- 1992
- Tongue
- English
- Weight
- 354 KB
- Volume
- 21
- Category
- Article
- ISSN
- 1097-6760
No coin nor oath required. For personal study only.
✦ Synopsis
Study objective: To determine if a single dose of intramuscular ketorolac given on presentation to the emergency department has a narcotic-sparing effect in adult patients with sickle cell vaso-occlusive crisis pain.
Design: A prospective, randomized, single-dose, double-blind study.
Setting: ED of a university hospital and an affiliated county hospital.
Type of participants:
Eighteen adult patients who presented to the ED with sickle cell crisis pain a total of 24 times.
Interventions: Patients were randomized to receive either ketorolac 60 mg IM or placebo on presentation to the ED. Subjects were administered meperidine on presentation and then received a standardized dose of meperidine every 30 minutes during the four-hour observation period based on the severity of pain.
Measurements and main results: The 12 subjects in the ketorolac group received an average of 231 + 92 mg meperidine, whereas the 12 subjects in the placebo group received an average meperidine dose of 250 _+ 85 mg (P= .61 ).
Conclusion:
The use of intramuscular ketorolac did not lead to a clinically significant reduction in the requirement for narcotics during the four-hour ED treatment period.
[Wright SW, Norris RL, Mitchell TR: Ketorolac for sickle cell vaso-occlusive crisis pain in the emergency department: Lack of a narcotic-sparing effect.